Technical Analysis for GLPG - Galapagos NV
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 28.76 | 0.45% | 0.13 |
Earnings due: May 2
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bullish Engulfing | Bullish | 0.00% | |
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | 0.45% | |
Hammer Candlestick | Bullish | 0.45% | |
New 52 Week Low | Weakness | 0.45% | |
Oversold Stochastic | Weakness | 0.45% | |
New 52 Week Closing Low | Bearish | -0.03% | |
New 52 Week Low | Weakness | -0.03% | |
Oversold Stochastic | Weakness | -0.03% |
Alert | Time |
---|---|
Hammer Candlestick Entry | about 7 hours ago |
Rose Above Previous Day's High | about 7 hours ago |
60 Minute Opening Range Breakout | about 8 hours ago |
Down 1% | about 11 hours ago |
60 Minute Opening Range Breakdown | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Galapagos NV Description
Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Acid Clinical Development Autoimmune Disease Inflammation Monoclonal Antibodies Inflammatory Diseases Rheumatoid Arthritis Psoriasis Inflammatory Bowel Disease Ulcerative Colitis Osteoarthritis Ulcer Abdominal Pain Colitis Cystic Fibrosis Arthritis Fatty Acids Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases Janus Kinase Morphosys Treatment Of Inflammation
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 45.16 |
52 Week Low | 28.33 |
Average Volume | 135,386 |
200-Day Moving Average | 36.79 |
50-Day Moving Average | 33.22 |
20-Day Moving Average | 30.33 |
10-Day Moving Average | 29.12 |
Average True Range | 0.54 |
RSI (14) | 22.48 |
ADX | 44.75 |
+DI | 14.68 |
-DI | 40.56 |
Chandelier Exit (Long, 3 ATRs) | 31.37 |
Chandelier Exit (Short, 3 ATRs) | 29.96 |
Upper Bollinger Bands | 32.94 |
Lower Bollinger Band | 27.72 |
Percent B (%b) | 0.2 |
BandWidth | 17.23 |
MACD Line | -1.32 |
MACD Signal Line | -1.33 |
MACD Histogram | 0.0125 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 29.56 | ||||
Resistance 3 (R3) | 29.50 | 29.19 | 29.42 | ||
Resistance 2 (R2) | 29.19 | 28.98 | 29.21 | 29.38 | |
Resistance 1 (R1) | 28.97 | 28.86 | 29.08 | 29.03 | 29.33 |
Pivot Point | 28.66 | 28.66 | 28.71 | 28.68 | 28.66 |
Support 1 (S1) | 28.44 | 28.45 | 28.55 | 28.50 | 28.19 |
Support 2 (S2) | 28.13 | 28.33 | 28.15 | 28.14 | |
Support 3 (S3) | 27.91 | 28.13 | 28.10 | ||
Support 4 (S4) | 27.97 |